Angiocrine Bioscience Announces Oral Presentation of AB-205 Data during the 47th Annual Meeting of the European Society for Blood and Marrow Transplantation

Share this article
Share this article
SAN DIEGO, March 12, 2021 /PRNewswire/ -- Angiocrine Bioscience Inc., a clinical-stage biopharmaceutical company today announced that they have been selected by the European Society for Blood and Marrow Transplantation (EBMT) for an oral presentation of from AB-205-001, a Phase 1b/2 study to prevent progression to severe organ toxicities in lymphoma subjects undergoing curative high-dose consolidation therapy with autologous hematopoietic cell transplantation (HDT-AHCT).
"Our investigators and Angiocrine are honored to be selected by EBMT to present at its annual meeting this March," commented Paul Finnegan, MD, Angiocrine CEO. "We look forward to Dr. Caroline Mulroney's presentation of AB-205's efficacy and safety results from our Phase 1b/2 study as well as preparing for the upcoming Phase 3 registration study for this indication."  

Related Keywords

Johnr Jaskowiak ,Paul Finnegan ,Angiocrine Bioscience ,Caroline Mulroney ,European Society For Blood ,Drug Administration ,Angiocrine Bioscience Inc ,European Society ,Marrow Transplantation ,Open Label Dose Escalation Trial ,Systemic Lymphoma Undergoing High Dose Therapy ,Autologous Hematopoietic Cell Transplantation ,On Demand Library ,Oral Session ,Cellular Therapy ,Gene Therapy ,New Drugs ,European Time ,Regenerative Medicine Advanced Therapy ,Orphan Drug Designation ,Advanced Reparative Medicines ,Inc ,பால் ஃபிநிகெந் ,ஐரோப்பிய சமூகம் க்கு இரத்தம் ,ஐரோப்பிய சமூகம் ,மஜ்ஜை மாற்று அறுவை சிகிச்சை ,ஆன் தேவை நூலகம் ,வாய்வழி அமர்வு ,செல்லுலார் சிகிச்சை ,கீந் சிகிச்சை ,புதியது மருந்துகள் ,ஐரோப்பிய நேரம் ,ஆர்ஃபந் மருந்து பதவி ,இன்க் ,